InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
10%
T+90 mean return
-25.2%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Werner Milton H., Chairman & CEO. Insider active across 2 companies, notably Inhibikase Therapeutics, Inc.. Aggregated, 11 disclosures have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €76k. Activity tracked since 14 May 2021. The latest transaction was disclosed on 16 August 2022 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations11 total
5,000 shares@ US$0.802.6% of flowCommon StockSEC:0000899243-22-028794:0
Ideal exit: 13 May 2023 (T+270)
5,000 shares@ US$0.9760.0020% mcap3.1% of flowCommon StockSEC:0000899243-22-020094:0
Ideal exit: 21 Feb 2023 (T+270)
10,000 shares@ US$0.600.0025% mcap3.9% of flowCommon StockSEC:0000899243-22-019229:0
Ideal exit: 14 Feb 2023 (T+270)
21,853 shares@ US$2.0236.2% of flowCommon StockSEC:0001104659-22-001168
21,853 shares@ US$2.020.017% mcap26.8% of flowCommon StockSEC:0001104659-22-001168:0
17,569 shares@ US$1.980.013% mcap21.2% of flowCommon StockSEC:0001104659-21-141628:0
Ideal exit: 14 Aug 2022 (T+270)
17,569 shares@ US$1.9828.7% of flowCommon StockSEC:0001104659-21-141628
Ideal exit: 14 Aug 2022 (T+270)
21,853 shares@ US$2.020.017% mcap26.0% of flowCommon StockSEC:0000899243-21-033598:0
21,853 shares@ US$2.0235.2% of flowCommon StockSEC:0000899243-21-033598
43,707 shares@ US$0.380.0060% mcap9.5% of flowCommon StockSEC:0000899243-21-019788:0
43,707 shares@ US$0.389.5% of flowCommon StockSEC:0000899243-21-019788
11 of 11 declarations
About Werner Milton H.
Milton H. Werner is the President and CEO of Inhibikase Therapeutics, Inc. He leads the company with a strategic vision, overseeing operations and research and development initiatives. Milton is responsible for implementing corporate strategies and managing stakeholder relationships. His experience in the biopharmaceutical sector is a valuable asset for the leadership of Inhibikase.
